Cisplatin/carboplatin plus etoposide

DRUG2 trials

Sponsors

EpicentRx, Inc.

Conditions

Carcinoma, Small Cell Lung

Phase 3

RRx-001 Sequentially With a Platinum Doublet or a Platinum Doublet in Third-Line or Beyond in Patients With Small Cell Lung Cancer

TerminatedNCT03699956

EpicentRx, Inc.Carcinoma, Small Cell Lung

Start: 2018-12-24End: 2024-03-01Updated: 2024-03-26

A Phase 3, Controlled, Open-label, Global Randomized Study of RRx-001 With a Platinum Doublet or a Platinum Doublet in Small Cell Lung Cancer

Active, not recruitingNCT05566041

EpicentRx, Inc.Carcinoma, Small Cell Lung

Start: 2022-08-01End: 2025-12-31Target: 292Updated: 2024-10-31

Related Papers

A multicenter, phase 1, dose escalation clinical trial (G-FORCE-1) of XRT, RRx-001 and temozolomide followed by temozolomide +/- RRx-001 in newly diagnosed glioblastoma

Frontiers in Oncology2023-06-059 citations

Cardioprotection from Acute Myocardial Infarction with RRx-001, an NLRP3 Inflammasome Inhibitor, in Phase 3 for the Treatment of Cancer

Physiology2023-05-01

A Review of RRx-001: A Late-Stage Multi-Indication Inhibitor of NLRP3 Activation and Chronic Inflammation.

2023-03-1528 citations

An explorary analysis of a COVID-truncated REPLATINUM phase 3 trial in SCLC.

Journal of Clinical Oncology2021-05-202 citations

In small cell lung cancer patients treated with RRx-001, a downregulator of CD47, decreased expression of PD-L1 on circulating tumor cells significantly correlates with clinical benefit.

2021-01-0116 citations

Desperate Times, Desperate Measures: The Case for RRx-001 in the Treatment of COVID-19.

2020-07-0710 citations

Correlation of decreased expression of PD-L1 on circulating tumor cells and clinical benefit in SCLC Patients treated with RRx-001, a CD47 downregulator, in a phase II trial.

Journal of Clinical Oncology2020-05-20

REPLATINUM Phase III Randomized Study: RRx-001 + Platinum Doublet Versus Platinum Doublet in Third-Line Small Cell Lung Cancer

Future Oncology2019-09-1149 citations

RRx-001 followed by platinum plus etoposide in patients with previously treated small-cell lung cancer

British Journal of Cancer2019-06-2339 citations